| Ytd | 175.58% | |
| 1y | 195.20% |
| Open | 34.85 | Prev Close | 34.18 | Low | 34.57 | High | 38.04 | Mkt Cap | 4.96B |
| Vol | 2.77M | Avg Vol | 2.13M | EPS | -3.70 | P/E | N/A | Forward P/E | -19.02 |
| Beta | 2.19 | Short Ratio | 5.76 | Inst. Own | 88.48% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 40.56 | 200-d Avg | 27.87 | 1yr Est | 72.33 |
DFTX News
JP Morgan initiates coverage on Definium Therapeutics (NASDAQ:DFTX) with a Overweight rating and a
Canaccord Genuity analyst Sumant Kulkarni maintains Definium Therapeutics (NASDAQ:DFTX) with a Bu
Baird analyst Christopher Chen maintains Definium Therapeutics (NASDAQ:DFTX) with a Outperform a
Definium Therapeutics announced positive Phase 3 Panorama trial results for DT120 in generalized anx
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Definium Therapeutics (NASDAQ:DFTX
Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) stock moved upwards by 44.6% to $2.4 during Monday&
Needham analyst Ami Fadia reiterates Definium Therapeutics (NASDAQ:DFTX) with a Buy and maintains
Study met primary and all key secondary efficacy endpoints; Panorama is the second positive Phase 3
RBC Capital analyst Brian Abrahams reiterates Definium Therapeutics (NASDAQ:DFTX) with a Outperfo
Emerge Phase 3 study podium poster to be featured in "Latest Discoveries & Emerging Trends i
https://www.bloomberg.com/news/articles/2026-09-08/fda-s-acting-drug-vaccine-regulators-tapped-for-p
The designation was supported by the significant unmet medical need in MDD and results from the Comp
Top analysts changed outlook on top names. See analyst ratings page for all changes.
B of A Securities analyst Tazeen Ahmad initiates coverage on Definium Therapeutics (NASDAQ:DFTX)
Jones Trading analyst Justin Walsh maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and r
Canaccord Genuity analyst Sumant Kulkarni maintains Definium Therapeutics (NASDAQ:DFTX) with a Bu
RBC Capital analyst Brian Abrahams maintains Definium Therapeutics (NASDAQ:DFTX) with a Outperfor
Wells Fargo analyst Benjamin Burnett maintains Definium Therapeutics (NASDAQ:DFTX) with a Overwei
Baird analyst Christopher Chen maintains Definium Therapeutics (NASDAQ:DFTX) with a Outperform a
Needham analyst Ami Fadia maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises the
Definium Therapeutics says positive Phase 3 trial results for DT120, shows significant and rapid sym
Gainers Bone Biologics (NASDAQ:BBLG) stock moved upwards by 17.7% to $1.07 during Wednesday's p
Topline results from Voyage, its first Phase 3 study of DT120 (lysergide) Orally Disintegrating Tabl
Piper Sandler analyst David Amsellem reiterates Definium Therapeutics (NASDAQ:DFTX) with a Overwe
Wells Fargo analyst Benjamin Burnett initiates coverage on Definium Therapeutics (NASDAQ:DFTX) wi
Piper Sandler analyst David Amsellem reiterates Definium Therapeutics (NASDAQ:DFTX) with a Overwe
GH Research and Definium Therapeutics stocks rose after Eli Lilly agreed to buy AtaiBeckley in a dea
GAD affects approximately 26 million U.S. adults, and when left untreated, can cause chronic, pervas
Data highlight the challenges of achieving response and sustained remission in newly diagnosed and e
Stifel analyst Paul Matteis maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises t
Canaccord Genuity analyst Sumant Kulkarni maintains Definium Therapeutics (NASDAQ:DFTX) with a Bu
Health care stocks flashing warning to momentum investors. RSI indicator shows overbought for DFTX,
Dow Jones index gained 200 points; Acuity Inc (NYSE: AYI) reported better-than-expected financial re
Jones Trading analyst Justin Walsh maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and r
Definium Therapeutics (DFTX) stock hits $38.24 after positive clinical data, but an 84.57 RSI signal
Top Wall Street analysts changed their outlook on top names. Complete view of changes, incl. upgrade
Baird analyst Christopher Chen maintains Definium Therapeutics (NASDAQ:DFTX) with a Outperform a
Needham analyst Ami Fadia maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises the
Definium Therapeutics, Inc. (NASDAQ:DFTX) (the "Company" or "Definium"), a late-stag
Leerink Partners analyst Marc Goodman maintains Definium Therapeutics (NASDAQ:DFTX) with a Outper
Oppenheimer analyst Jay Olson maintains Definium Therapeutics (NASDAQ:DFTX) with a Outperform and
Gainers Tenon Medical (NASDAQ:TNON) stock moved upwards by 79.6% to $0.63 during Monday's regul
U.S. stocks up with Dow Jones gaining 200+ points. AbbVie Inc. announced acquisition of Apogee Thera
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling more than 300 poi
Definium shares are surging Monday after the company announced positive topline results from its Pha
Gainers Tenon Medical (NASDAQ:TNON) shares increased by 115.8% to $0.76 during Monday's pre-mar
Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical bio
Definium Therapeutics, Inc. (NASDAQ:DFTX) ("Definium" or the "Company"), a late-stag
Health officials explored restricting specific antidepressants among SSRI drugs-sources
Piper Sandler analyst David Amsellem maintains Definium Therapeutics (NASDAQ:DFTX) with a Overwei